The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Learn how semaglutide boosts health but also increases health care spending for patients. Keep reading to explore more.

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Weight Loss RX Reviews today published their groundbreaking "2025 American Compounded Semaglutide Consumer Insight Report" – ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

Oral semaglutide, known as the oral version of Ozempic, is revolutionising chronic disease management beyond just blood sugar ...

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...